Rhumbline Advisers Alnylam Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

  • $105 Billion
  • Q2 2024

A detailed history of Rhumbline Advisers transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 173,327 shares of ALNY stock, worth $47.3 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
173,327
Previous 173,689 0.21%
Holding current value
$47.3 Million
Previous $26 Million 62.26%
% of portfolio
0.04%
Previous 0.03%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024
BUY
$143.31 - $247.0 $24.8 Million - $42.8 Million
173,327 New
173,327 $42.1 Million
Q1 2024

May 09, 2024
BUY
$146.51 - $198.2 $119,552 - $161,731
816 Added 0.47%
173,689 $26 Million
Q4 2023

Feb 08, 2024
BUY
$151.41 - $196.57 $121,430 - $157,649
802 Added 0.47%
172,873 $33.1 Million
Q3 2023

Nov 09, 2023
SELL
$170.77 - $211.65 $557,222 - $690,613
-3,263 Reduced 1.86%
172,071 $30.5 Million
Q2 2023

Aug 08, 2023
BUY
$185.01 - $212.05 $3.23 Million - $3.7 Million
17,439 Added 11.04%
175,334 $33.3 Million
Q1 2023

May 11, 2023
BUY
$182.66 - $235.53 $1.74 Million - $2.24 Million
9,499 Added 6.4%
157,895 $31.6 Million
Q4 2022

Feb 14, 2023
BUY
$185.53 - $241.31 $2.17 Million - $2.83 Million
11,711 Added 8.57%
148,396 $35.3 Million
Q3 2022

Nov 10, 2022
BUY
$138.54 - $232.0 $1.13 Million - $1.9 Million
8,174 Added 6.36%
136,685 $27.4 Million
Q2 2022

Aug 11, 2022
BUY
$120.42 - $169.29 $1.52 Million - $2.14 Million
12,634 Added 10.9%
128,511 $18.7 Million
Q1 2022

May 12, 2022
SELL
$127.18 - $173.91 $502,996 - $687,814
-3,955 Reduced 3.3%
115,877 $18.9 Million
Q4 2021

Feb 10, 2022
BUY
$159.56 - $209.29 $594,041 - $779,186
3,723 Added 3.21%
119,832 $20.3 Million
Q3 2021

Nov 12, 2021
SELL
$169.75 - $207.73 $51,943 - $63,565
-306 Reduced 0.26%
116,109 $21.9 Million
Q2 2021

Aug 05, 2021
SELL
$128.63 - $176.89 $721,357 - $991,999
-5,608 Reduced 4.6%
116,415 $19.7 Million
Q1 2021

May 06, 2021
SELL
$126.83 - $175.69 $576,949 - $799,213
-4,549 Reduced 3.59%
122,023 $17.2 Million
Q4 2020

Feb 10, 2021
SELL
$122.97 - $147.0 $900,878 - $1.08 Million
-7,326 Reduced 5.47%
126,572 $16.5 Million
Q3 2020

Nov 12, 2020
SELL
$121.19 - $165.49 $797,066 - $1.09 Million
-6,577 Reduced 4.68%
133,898 $19.5 Million
Q2 2020

Aug 13, 2020
BUY
$104.21 - $156.44 $2.97 Million - $4.46 Million
28,498 Added 25.45%
140,475 $20.8 Million
Q1 2020

May 06, 2020
BUY
$93.12 - $133.99 $546,800 - $786,789
5,872 Added 5.53%
111,977 $12.2 Million
Q4 2019

Feb 05, 2020
BUY
$74.51 - $124.23 $227,926 - $380,019
3,059 Added 2.97%
106,105 $12.2 Million
Q3 2019

Oct 23, 2019
SELL
$70.9 - $87.82 $638 - $790
-9 Reduced 0.01%
103,046 $8.29 Million
Q2 2019

Aug 14, 2019
BUY
$65.86 - $92.79 $669,401 - $943,117
10,164 Added 10.94%
103,055 $7.48 Million
Q1 2019

May 01, 2019
BUY
$72.76 - $93.45 $166,984 - $214,467
2,295 Added 2.53%
92,891 $8.68 Million
Q4 2018

Jan 31, 2019
SELL
$62.67 - $88.33 $366,556 - $516,642
-5,849 Reduced 6.06%
90,596 $6.61 Million
Q3 2018

Nov 07, 2018
SELL
$87.52 - $122.67 $131,367 - $184,127
-1,501 Reduced 1.53%
96,445 $8.44 Million
Q2 2018

Aug 06, 2018
BUY
$88.31 - $107.8 $228,811 - $279,309
2,591 Added 2.72%
97,946 $9.65 Million
Q1 2018

May 02, 2018
SELL
$115.92 - $148.54 $528,595 - $677,342
-4,560 Reduced 4.56%
95,355 $11.4 Million
Q4 2017

Feb 09, 2018
BUY
$114.49 - $139.98 $841,158 - $1.03 Million
7,347 Added 7.94%
99,915 $12.7 Million
Q3 2017

Nov 06, 2017
BUY
$72.53 - $118.27 $6.71 Million - $10.9 Million
92,568
92,568 $10.9 Million

Others Institutions Holding ALNY

# of Institutions
639
Shares Held
107M
Call Options Held
2.33M
Put Options Held
2.15M
View Full List

About ALNYLAM PHARMACEUTICALS, INC.

ALNY Quotes by TradingView
  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $33.6B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email